By simultaneously targeting the Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP), and Glucagon receptors, this peptide provides a multi-dimensional approach to studying metabolic homeostasis
Step 03 Start Your Journey Access personalized care, resources, and support from professionals and Fridays members on our platform
Many patients end up paying out-of-pocket for the medication, since their insurance plans dont cover weight loss drugs
Gastrointestinal issues dominate, including nausea (44-50 percent of patients), vomiting (24-31 percent), diarrhea (30-40 percent), constipation (24-30 percent), and abdominal pain (20-25 percent)
Keeping a food and exercise journal can provide motivation and help identify patterns that work best for you